Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120047) titled 'A Phase I Clinical Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for High Risk, Recurrent/Refractory Neuroblastoma in Children' on March 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Neuroblastoma
Intervention:
First dose group:Umbilical cord blood natural killer cells, 0.33x10^7/kg/time/person, with the first four administrations given once a week and the last four administrations given once every two weeks,a total of 8 times
Second dose group:Umbilical cord blood natural killer cells, 0.99x10^7/kg/time/perso...